BOSTON--(BUSINESS WIRE)--Abiomed (Nasdaq: ABMD) will highlight how Impella heart pumps help heart teams achieve more complete high-risk revascularization and heart recovery in the catheterization lab ...

The FDA typically requires post-approval studies for medical devices that receive a PMA, the FDA’s highest level of regulatory approval. FDA post-approval studies use high-quality prospective data to ...

As an example of how this technology might be used in future clinical practice, Abiomed has already trained an AI algorithm to predict the next five minutes of a patient’s arterial pressure based only ...

TCT Connect attendees are also invited to visit Abiomed’s virtual booth, which will open at 7:00 a.m. EDT on October 14 on ProtectedPCI.com, to learn more about the Impella heart pump portfolio and ...

DANVERS, Mass. – October 24, 2024 – Novel data on the benefits of Impella ® heart pump technology in high-risk percutaneous coronary intervention (PCI) and cardiogenic shock will be presented during ...

The Impella heart pump is a small pump that a healthcare professional can insert without surgery. It can help maintain blood flow in people who have CAD, are recovering from cardiogenic shock, or are ...

Please provide your email address to receive an email when new articles are posted on . Risk for death was lower with the pump vs. standard care only, but incidence of adverse events was elevated. The ...